Showing results (11-20 of 16) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
The Oncologist|February 28, 2024
Clinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver OncogenesThomas Stricker, Neha Jain, Esprit Ma, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2012
Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancerJavier Cortés, Pierre Fumoleau, Giulia Valeria Bianchi, et al.Breast Cancer Research : BCR|February 11, 2017
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancerGiampaolo Bianchini, Astrid Kiermaier, Giulia Valeria Bianchi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2023
MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid TumorsChristopher J Sweeney, John D Hainsworth, Ron Bose, et al.Molecular Oncology|May 28, 2025
Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumabCharles Swanton, Russell W Madison, Candice Francheska B Tambaoan, et al.The Lancet. Oncology|December 14, 2011
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialLuca Gianni, Tadeusz Pienkowski, Young-Hyuck Im, et al.Pageof 2